Prometheus Biosciences In...

NASDAQ: RXDX · Real-Time Price · USD
199.92
0.18 (0.09%)
At close: Jun 15, 2023, 10:00 PM

Prometheus Biosciences Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net Income
-141.75M -90.19M -31.14M
Depreciation & Amortization
629K 258K 109K
Stock-Based Compensation
20.86M 10.7M 739K
Other Working Capital
-3.46M 16.05M 6.67M
Other Non-Cash Items
865K 2.26M 1.69M
Deferred Income Tax
-2.68M 659K 1.91M
Change in Working Capital
-1.18M 12.82M -1.33M
Operating Cash Flow
-123.25M -63.51M -28.02M
Capital Expenditures
-2.7M -1.14M -204K
Cash Acquisitions
403.78M n/a n/a
Purchase of Investments
-478.68M n/a n/a
Sales Maturities Of Investments
77.6M n/a n/a
Other Investing Acitivies
-403.78M n/a -859K
Investing Cash Flow
-403.78M -1.14M -1.06M
Debt Repayment
n/a n/a n/a
Common Stock Repurchased
n/a 428K n/a
Dividend Paid
n/a -428K n/a
Other Financial Acitivies
562.2M 268.12M 79.89M
Financial Cash Flow
562.2M 267.69M 79.89M
Net Cash Flow
35.17M 203.05M 50.8M
Free Cash Flow
-125.96M -64.64M -28.22M